HPS Pharmacies wish to advise that the Therapeutic Goods Administration (TGA) has issued a safety alert for ranitidine products. Ranitidine is available in a range of prescription and non-prescription medications, including tablets, oral liquid, and solution for injection.
This safety alert has been initiated following international reports of contamination of ranitidine medicines with the impurity, N-nitrosodimethylamine (NDMA). NDMA is classified as a probable human carcinogen and can be found in low levels in a variety of foods, some drinking water, and air pollution.
The TGA advises that the risk posed by NDMA at the levels currently identified in ranitidine medicines is very low. For individuals prescribed ranitidine, the risks of not treating their condition may be greater than the risks associated with potential exposure to NDMA. It is advised that these patients continue taking ranitidine until they have discussed alternatives with their doctor.
Possible alternatives include:
- An alternate H2 receptor antagonist;
- A proton pump inhibitor; and/or
- Diet and lifestyle modification.
Retain this notice in a prominent position, including in other related business units for one month. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact your pharmacist at HPS Pharmacies.
Subscribe Knowledge Centre Updates
Enter your details to receive Knowledge Centre updates